Intermittent plasmapheresis prevents recurrence in neuromyelitis optica.
about
Treatment of neuromyelitis optica: state-of-the-art and emerging therapiesGuidelines on the Use of Therapeutic Apheresis in Clinical Practice-Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Seventh Special Issue.Current concept of neuromyelitis optica (NMO) and NMO spectrum disorders.Clinical spectrum and treatment of neuromyelitis optica spectrum disorders: evolution and current status.Therapeutic plasma exchange in neuromyelitis optica: a case series.The treatment of neuromyelitis optica.Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica Study Group (NEMOS).New insights into neuromyelitis opticaNeuromyelitis optica: an antibody-mediated disorder of the central nervous system.Ex vivo spinal cord slice model of neuromyelitis optica reveals novel immunopathogenic mechanisms.Complement-dependent cytotoxicity in neuromyelitis optica requires aquaporin-4 protein assembly in orthogonal arraysCurrent options for the treatment of optic neuritis.Present and Future Therapies in Neuromyelitis Optica Spectrum DisordersNeutrophil protease inhibition reduces neuromyelitis optica-immunoglobulin G-induced damage in mouse brainImmunoadsorption in patients with neuromyelitis optica spectrum disorder.Immunotherapy of neuromyelitis optica.EFNS guidelines on diagnosis and management of neuromyelitis optica.Current and future treatment approaches for neuromyelitis optica.Treatment of neuromyelitis optica: an evidence based review.Plasma exchange in severe attacks of neuromyelitis optica.The blood compatibilities of blood purification membranes and other materials developed in Japan.Biotherapy in Inflammatory Diseases of the CNS: Current Knowledge and Applications.Th17 cells in neuromyelitis optica spectrum disorder: a review.Eosinophil pathogenicity mechanisms and therapeutics in neuromyelitis optica.Where Do AQP4 Antibodies Fit in the Pathogenesis of NMO?Maintenance plasma exchange therapy for steroid-refractory neuromyelitis optica.The top clinical trial opportunities in therapeutic apheresis and neurology.Diagnostik und Therapie der Neuromyelitis opticaNeuromyelitis optica should be classified as an astrocytopathic disease rather than a demyelinating disease
P2860
Q28245749-8E20A2E6-F0BA-4CA6-866E-70FED68B0972Q30276550-C4E356D2-6247-4308-9019-1A2EFDA38F9FQ30577078-3154505A-F5FE-4E54-8649-53E948B2F18AQ30676331-5A473561-3E1F-4E27-8421-1A073D64F32AQ34378423-ED58C404-CE6C-48EE-AF19-351352941A5EQ34399291-18A25373-96B5-403A-9708-736AE60529D9Q35052199-839B51E8-659C-440C-AEFA-0463F3B825C8Q35539641-B3E8F5CD-B43B-4ED8-AF8E-E0039E9AE35DQ35738898-53454B87-8A08-4758-80F6-FAECEA49AE9CQ35870397-A7B90D49-EA45-49EF-A9D3-BA97FA365E83Q35922319-E640EA5E-1DA1-439E-BAC6-D164962CEDECQ36173222-9F91DD2E-FB5F-4EDC-881D-1D8875EE3131Q36484394-FCAAF57E-0619-4E53-8103-DE8DF8709963Q36814107-16C91375-4D70-4D12-BF3A-7486FFD4FA23Q37027700-31821159-550B-4321-8F86-36ACA2294CF1Q37456974-220FE52E-3017-45EC-982A-7B6B49890D8EQ37763266-C32E9A04-0D6A-4C87-81B2-39C26E9C8D01Q37892874-A51752CA-9E04-4575-B636-5C3F088F243BQ37973248-09BDF155-34FD-4DE3-A3FB-8BCAFCCD9156Q37999792-ACED7893-3211-4CD1-8B45-49EA8D8549C0Q38586090-42B5DBB6-BB5B-43AF-8BD0-C3A39FC44C83Q38729214-66F090F1-1DFD-456E-B5AC-0511B5F568C2Q38765404-B6685537-394D-475B-BB6F-F359F042D94CQ40092095-A8C694D1-0F58-4CAA-A10A-14D3B78AA52DQ42560864-B2C62999-52F0-484B-B288-D53EE453D9A4Q47926002-30BF3061-47E7-4BCD-8D42-418026163155Q48894285-2928139E-80E8-44F6-BD43-45445D4B6C6CQ56986486-2376F502-5130-45C5-B01C-BF10D547D523Q57725942-964C09DF-9215-4802-8592-0D14B40C33E1
P2860
Intermittent plasmapheresis prevents recurrence in neuromyelitis optica.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Intermittent plasmapheresis prevents recurrence in neuromyelitis optica.
@en
Intermittent plasmapheresis prevents recurrence in neuromyelitis optica.
@nl
type
label
Intermittent plasmapheresis prevents recurrence in neuromyelitis optica.
@en
Intermittent plasmapheresis prevents recurrence in neuromyelitis optica.
@nl
prefLabel
Intermittent plasmapheresis prevents recurrence in neuromyelitis optica.
@en
Intermittent plasmapheresis prevents recurrence in neuromyelitis optica.
@nl
P1476
Intermittent plasmapheresis prevents recurrence in neuromyelitis optica.
@en
P2093
Katsuichi Miyamoto
Susumu Kusunoki
P304
P356
10.1111/J.1744-9987.2009.00780.X
P577
2009-12-01T00:00:00Z